Molecular malignancy in melanocytic lesions

US9758829B2 · kind B2 · utility

Assignees

• HTG Molecular Diagnostics, Inc. · US
• JOHN WAYNE CANCER INSTITUTE · US

Inventors

• Hui Wang · San Bruno, US
• Christopher John Roberts · Canton, US
• Krishna Maddula · Tucson, US
• Zhenquiang Lu · Tucson, US
• Tom Vasicek · Minneapolis, US
• B J Kerns · Madison, US
• Bruce E. Seligmann · Tucson, US
• Dave S.B. Hoon · Los Angeles, US

Key dates

• Filing date: Jun 24, 2013
• Grant date: Sep 12, 2017
• Expiry date: Jun 30, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/178
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.